Calcium channel blocker

Insights on the Systemic Scleroderma Treatment Global Market to 2028 - Featuring Roche, United Therapeutics & Boehringer Ingelheim International Among Others

Retrieved on: 
Monday, March 1, 2021
Autoimmune diseases, Organ systems, Medical specialties, Mucinoses, Anatomy, Connective tissue diseases, Systemic scleroderma, Scleroderma, Systemic, Calcium channel blocker

Global Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)

Key Points: 
  • Global Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
    5.3.1.
  • Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016-2028 (USD Million)
    5.4.1.
  • Global Systemic Scleroderma Treatment Market, by Phosphodiesterase 5 inhibitors-PHA, by Region, 2016-2028 (USD Million)
    5.5.1.
  • Global Systemic Scleroderma Treatment Market, by Calcium Channel Blockers, by Region, 2016-2028 (USD Million)
    5.8.1.

Insights on the Worldwide Antihypertensive Drugs Industry to 2026 - Players Include Pfizer, Takeda Pharmaceutical & AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Health, Pharmaceutical, Antihypertensive agents, Beta blocker, Antihypertensive drug, Hypertension, Calcium channel blocker, Cardiovascular system, Circulatory system, Medicine

The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Antihypertensive drugs are employed for the treatment of patients suffering from hypertension.
  • Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs.
  • Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators.

Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 25, 2019
Health, Cardiology, Pharmaceutical, Branches of biology, Ion channels, Membrane proteins, Calcium channels, Electrophysiology, Integral membrane proteins, Membrane biology, Calcium channel blocker, Channel blocker, Voltage-gated calcium channel, Pipeline

The "Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Voltage-Dependent Calcium Channel Blockers development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Pipeline Products covered across the following Developmental Stages:
    Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.